Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Department of Dermatology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China; Laboratory of Dermatoimmunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
J Invest Dermatol. 2018 Sep;138(9):2024-2032. doi: 10.1016/j.jid.2018.03.1500. Epub 2018 Mar 17.
Cutaneous T cell lymphoma (CTCL) can have clinical and histological features resembling benign inflammatory dermatosis and can be difficult to diagnose. Very limited biomarkers are available for CTCL prognosis. We aimed to identify microRNA (miR) signatures to facilitate diagnostic and prognostic evaluations of CTCL. A cross-platform miR microarray identified 10 miRs that were differentially expressed between CTCL and benign inflammatory dermatosis patients. Subsequent reverse transcription polymerase chain reaction validation was used to generate a 5-miR-based diagnosing classifier, which showed high diagnostic accuracy in CTCL (area under the curve = 0.985 and 0.956 for training and testing set, respectively). Association between miR expressions and patient prognosis was studied. miR-155 and miR-200b were significantly associated with overall survival in CTCL patients, outperformed Ki-67. miR expressions were combined with Ki-67 to create a classifier for 5-year overall survival in CTCL patients. Our work provided miR signatures to facilitate CTCL diagnosis and prognosis with satisfying accuracy.
皮肤 T 细胞淋巴瘤（CTCL）可能具有类似于良性炎症性皮肤病的临床和组织学特征，因此难以诊断。目前用于 CTCL 预后的生物标志物非常有限。我们旨在确定 microRNA（miR）特征，以促进 CTCL 的诊断和预后评估。一个跨平台的 miR 微阵列确定了 10 个在 CTCL 和良性炎症性皮肤病患者之间表达差异的 miR。随后使用逆转录聚合酶链反应验证生成了一个基于 5 个 miR 的诊断分类器，该分类器在 CTCL 中显示出高诊断准确性（训练集和测试集的曲线下面积分别为 0.985 和 0.956）。研究了 miR 表达与患者预后之间的关系。miR-155 和 miR-200b 与 CTCL 患者的总生存率显著相关，优于 Ki-67。将 miR 表达与 Ki-67 相结合，为 CTCL 患者创建了一个用于 5 年总生存率的分类器。我们的工作提供了 miR 特征，以提高 CTCL 的诊断和预后准确性。
